Disordered Breathing Takes a Toll on Nighttime BP

BY DAMIAN McNAMARA
Miami Bureau

People with sleep-disordered breathing were less likely to experience a normal nighttime decrease in systolic blood pressure and were at increased risk of adverse cardiac and other outcomes, according to a new prospective study. Data from a previous study showed that most people experience a 10%-20% dip in blood pressure at nighttime (Hypertension 1995;26:60-9). Other data have shown an association between sleep apnea syndrome and a failure to experience the beneficial nighttime decrease in blood pressure, but the evidence is limited to cross-sectional studies (Am. J. Hypertens. 2001;14:887-92; Chest 2002;122:1148-55).

The current study’s findings are important because ‘nocturnal nondipping’ associated with sleep-disordered breathing (SDB) has been linked in earlier studies to target organ damage and a poor cardiovascular prognosis (Can. J. Cardiol. 2007;23:132-6; JAMA 1999;282:539-46).

Dr. Khin Mae Hla and her associates of the departments of medicine and population health sciences at the University of Wisconsin, Madison, assessed 328 adults in the ongoing Wisconsin Sleep Cohort Study. Mean patient age was 49 years, 63% were men, and the mean body mass index was 29 kg/m². The subjects had a baseline polysomnography study and at least 24-hour ambulatory blood pressure monitoring assessments during an average 7.2 years of follow-up. Of the total, 18% developed systolic nondipping, and 11% developed diastolic nondipping. No association was found between SDB and diastolic nondipping, but the longitudinal association with systolic BP alterations was significant (Sleep 2008;31:795-800).

The chances of developing systolic nondipping were significantly correlated with baseline SDB severity in a dose-response fashion. Patients scoring less than 5 on the Apnea-Hypopnea Index (no or minimal SDB) were used as a reference group. Those with mild SDB (score of 5 to 15) were three times as likely to develop systolic nondipping (adjusted odds ratio, 3.1), and those with moderate to severe SDB (score of 15 or greater) were more than four times as likely to develop systolic nondipping (OR, 4.4).

COPD May Point To Obstructive Sleep Apnea

BALTIMORE — Two measures of lung function—a higher forced expiratory volume in 1 second/forced vital capacity ratio and lower total lung capacity—may predict the presence of obstructive sleep apnea in chronic pulmonary disease patients, according to a poster presented at the annual meeting of the Associated Professional Sleep Societies.

Dr. Ramez Sunna and colleagues at the University of Missouri, Columbia, reviewed all adult patients who underwent both pulmonary function testing and polysomnography between 2000 and 2007 at a tertiary care medical center. Overall, 279 patients (61%) met the criteria for obstructive sleep apnea (OSA), 167 patients (37%) met the criteria for chronic obstructive pulmonary disease (COPD), and 11 patients (2%) did not have either condition. A total of 101 patients (60%) had both COPD and OSA, but there was no significant correlation between the severity of the COPD and the severity of the OSA.

The researchers analyzed the COPD patients independently and found that those with both COPD and OSA had a significantly higher forced expiratory volume in one second (FEV₁/FVC) ratio, compared with COPD patients without OSA (61.03% vs. 54.61%), although both of these values fell below healthy levels. The association remained significant after controlling for variables.

For your patients with type 2 diabetes, start once-daily Levenir™

Levenir™ helps patients with diabetes achieve their A1C goal.
- 24-hour action at a once-daily dose
- Provider consistent with action, day after day
- Less weight gain

For more information about Levenir™, please visit novonordisk.com/Levenir

I have type 2 diabetes, This is my glucose control.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levenir™. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Close monitoring is recommended for all patients with diabetes. Levenir™ is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Corrected and uncorrected treatment may require adjustment.

Hypoglycemia or decompensation of treatment may lead to hypoglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levenir™ should not be diluted or mixed with any other insulin preparations. Alcohol may cause cardiac arrhythmias, and severe, particularly it prevalent, poor metabolic control is improved by intensified insulin therapy. Close and frequent monitoring of insulin administration will be needed to reduce the risk of hypoglycemia in patients being switched to Levenir™ from other insulins or long-acting insulin preparations. The dose of Levenir™ may be adjusted in patients with renal or hepatic impairment, Other adverse events commonly associated with insulin therapy may include injection site reactions (e.g., swelling, inflammation), and pain, flushing, headache, and peripheral edema.

Whether these observed differences represent true differences in the effects of Levenir™, in addition, insulin glargine is not dependent, since these trials were not blinded and the protocols (e.g., diet and exercise instructions and monitoring) were not specifically designed at capturing hypoglycemia related to weight effects of the treatments compared. In the clinical trials, the incidence of hypoglycemia was not increased.

I have tried a list of Prescribing Information on the bottom page.

Levenir™ Insulin detemir (rDNA origin) injection

Please see brief summary of Prescribing Information on the bottom page.

Levenir™ and NovoSeven™ are registered trademarks of Novo Nordisk A/S, ◆ 2008 Novo Nordisk A/S, 1323451, May 2008

Heidi Splete

If you have any questions or concerns about Levenir™, please contact your healthcare professional.